ASH 2018 | Avapritinib for advanced systemic mastocytosis: analysis of patient-reported outcomes from EXPLORER

Daniel DeAngelo

Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, discusses the analysis of the patient-reported outcomes data for avapritinib, a potent inhibitor of KIT D816V for advanced systemic mastocytosis. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video